Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency

摘要: Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a major concern for oncological practise considering the increasing number of cancer survivors and lack standardised prevention or treatment [1]. The incidence CIPN depends on chemotherapy agent administered but is estimated occur in one third all patients undergoing [2, 3]. prevalence has been 68.1 % first month after administration neurotoxic agents 60 3 months post treatment. Patients were found still have 30% 6 more according results published systematic review conducted 2014 [4]. experiencing moderate severe report reduced quality life [5], chronic discomfort [6] disruption physical abilities general activities which can temporary permanent [5]. Currently clinical practise, assessed using common toxicity scales; however, these rely heavily patient’s subjective reports rather than quantitative testing [7]. potentially rescindable side effect although reversibility may dependent early detection identification modification Permanent reported, especially sensory symptoms lower extremities among treated with oxaliplatin up 11 years [8]. Early differential diagnosis need priority extending patients. previous history vitamin B12 deficiency identified as predisposing condition that increase risk developing However, who had no not tested before commences status. Moreover, potential develop during [9] therefore predispose patient and/ delaying development CIPN. We present case developed was deficient completing regimen. Upon administration, severity decreased allowed increased functional ability daily including walk.